Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

SHARE PURCHASE PURSUANT TO THE H SHARE INCENTIVE SCHEME AND ON-MARKET SHARE REPURCHASE

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company hereby announces that:

(1) it intends to utilize internal funds of up to RMB100 million for the professional trustee appointed by the Company in respect of the H share incentive scheme of the Company (the "**H Share Incentive Scheme**") to purchase H shares of the Company (the "**H Shares**") through on-market transactions and/or other permissible means in compliance with the H Share Incentive Scheme and applicable laws and regulations within twelve months from the date of this announcement at the time and frequency determined by the Board from time to time (the "**Share Purchase**"). The share awards to be granted under the H Share Incentive Scheme funded by existing shares purchased by the trustee will be subject to Rule 17.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); and

(2) it intends to exercise its powers under the general mandate granted by the shareholders of the Company (the "**Shareholders**") at the annual general meeting held on June 5, 2026 to repurchase H Shares in the open market within twelve months from the date of this announcement at the time and frequency determined by the Board from time to time (the "**Share Repurchase**"). The Share Repurchase is proposed to use up to RMB100 million for the repurchase of H Shares. The Company intends to hold the repurchased H Shares as treasury shares.

The Board believes that conducting the Share Purchase and the Share Repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and the Shareholders. The Group's current financial resources would enable it to implement the Share Purchase and the Share Repurchase with its internal resources while maintaining solid financial position for the continued growth of the Group's operation.

The Share Purchase and the Share Repurchase will be conducted in compliance with the articles of association of the Company, the Listing Rules and other applicable laws and regulations.

Shareholders and potential investors should note that the Share Purchase and the Share Repurchase are subject to market conditions and at the absolute discretion of the Board and there is no guarantee as to the timing, number or price of any Share Purchase or Share Repurchase. Therefore, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, June 8, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.